STOCK TITAN

Connect Biopharma to Participate in the Leerink Partners I&I and Metabolism Therapeutics Forum

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags
conferences

Rhea-AI Summary

Connect Biopharma Holdings (Nasdaq: CNTB), a biopharmaceutical company developing T cell-driven therapies for chronic inflammatory diseases, announced its participation in the Leerink Partners Inflammation and Immunology (I&I) and Metabolism Therapeutics Forum. The event is scheduled for July 9-10, 2024, in Boston, MA. Key executives including CEO Barry Quart, President David Szekeres, and CFO Steven Chan will host one-on-one investor meetings.

Loading...
Loading translation...
Argus Session date unavailable
-5.26% session move Open Argus
Details

News Market Reaction – CNTB

The recorded move for CNTB in the trading session of this news was -5.26%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

SAN DIEGO, CA and TIACANG, China, July 01, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect or the Company), a U.S.-headquartered, global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, announced today that Barry Quart, Chief Executive Officer, David Szekeres, President and Steven Chan, Chief Financial officer will be hosting one-on-one investor meetings at the Leerink Partners Inflammation and Immunology (I&I) and Metabolism Therapeutics Forum, taking place on July 9-10, 2024 in Boston, MA.

About Connect Biopharma Holdings Limited

Connect Biopharma is a global, clinical-stage biopharmaceutical company applying its expertise in T cell biology and drug discovery to develop innovative therapies to treat chronic inflammatory diseases with the goal of improving the lives of millions of those affected around the world. The Company is building a pipeline of proprietary small molecules and antibodies, using functional T cell assays, to screen and discover potent product candidates against validated immune targets. The Company’s lead product candidate, rademikibart (formerly known as CBP-201), is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα) in development for the treatment of atopic dermatitis and asthma. The Company’s second product candidate, icanbelimod (formerly known as CBP-307), is a modulator of S1P1 T cell receptors and is in development for the treatment of ulcerative colitis (UC). For more information, please visit: https://www.connectbiopharm.com/

INVESTOR CONTACT:

Tim McCarthy
LifeSci Advisors
tim@lifesciadvisors.com


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is Connect Biopharma's stock symbol?

Connect Biopharma's stock symbol is CNTB.

When is Connect Biopharma participating in the Leerink Partners I&I and Metabolism Therapeutics Forum?

Connect Biopharma will be participating in the Leerink Partners I&I and Metabolism Therapeutics Forum on July 9-10, 2024.

What will Connect Biopharma do at the Leerink Partners Forum?

Connect Biopharma's CEO Barry Quart, President David Szekeres, and CFO Steven Chan will host one-on-one investor meetings.

Where is the Leerink Partners I&I and Metabolism Therapeutics Forum taking place?

The Leerink Partners I&I and Metabolism Therapeutics Forum will take place in Boston, MA.

Who are the key executives from Connect Biopharma attending the Leerink Partners Forum?

The key executives attending the forum are CEO Barry Quart, President David Szekeres, and CFO Steven Chan.

Keep reading